November 28, 2016 - By Adrian Mccoy · 0 Comments
The stock of Cara Therapeutics Incorporated (NASDAQ:CARA) registered an increase of 42.22% in short interest. CARA’s total short interest was 3.82 million shares in November as published by FINRA. Its up 42.22% from 2.69M shares, reported previously. With 751,700 shares average volume, it will take short sellers 5 days to cover their CARA’s short positions. The short interest to Cara Therapeutics Incorporated’s float is 16.64%. About 798,516 shares traded hands. Cara Therapeutics Inc (NASDAQ:CARA) has risen 43.29% since April 25, 2016 and is uptrending. It has outperformed by 37.28% the S&P500.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $243.02 million. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It currently has negative earnings. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system.
Insitutional Activity: The institutional sentiment increased to 1.83 in Q2 2016. Its up 1.13, from 0.7 in 2016Q1. The ratio is positive, as 27 funds sold all Cara Therapeutics Inc shares owned while 20 reduced positions. 6 funds bought stakes while 27 increased positions. They now own 13.15 million shares or 19.13% less from 16.26 million shares in 2016Q1.
The Illinois-based Northern Trust has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Rhumbline Advisers last reported 0% of its portfolio in the stock. Cam Grp Hldg A S last reported 268,000 shares in the company. Deutsche Bancorporation Ag, a Germany-based fund reported 12,662 shares. Blackrock Fund Advsrs accumulated 903,747 shares or 0% of the stock. Baldwin Brothers Ma last reported 0.04% of its portfolio in the stock. Blackrock Institutional Trust Company Na holds 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 416,785 shares. American Group holds 0% or 12,094 shares in its portfolio. Tiverton Asset Mngmt Limited Liability Corp holds 583,468 shares or 2.42% of its portfolio. Magee Thomson Prtn Ltd Liability Com holds 0% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA) for 89 shares. Royal Commercial Bank Of Canada last reported 955 shares in the company. Dafna Management Limited Company holds 1.02% or 267,046 shares in its portfolio. Pictet Asset Mngmt Limited has invested 0.02% of its portfolio in Cara Therapeutics Inc (NASDAQ:CARA). Vanguard Grp holds 670,465 shares or 0% of its portfolio. Blackrock Advisors Lc accumulated 69,398 shares or 0% of the stock.
Out of 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cara Therapeutics has been the topic of 7 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock of Cara Therapeutics Inc (NASDAQ:CARA) earned “Buy” rating by Needham on Friday, July 24. The firm earned “Buy” rating on Thursday, October 13 by H.C. Wainwright. As per Wednesday, November 4, the company rating was initiated by Cantor Fitzgerald. As per Thursday, November 24, the company rating was maintained by Scotia Capital.
Cara Therapeutics, Inc., incorporated on July 2, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Firm operates through the activities related to the discovery and development of novel therapeutics to treat serious medical conditions, including pain and pruritus segment. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system. The Company’s product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy